0758 GMT - Haleon's full-year results are solid, with a 2025 outlook in line with consensus forecasts, RBC Capital Markets analysts say in a note. The British consumer-health company's 2024 results came in slightly ahead of consensus, despite analysts' and investors' concerns around a depressed North American flu season in 4Q, they say. For 2025, the company has guided for organic revenue growth to be in the range of 4% to 6% and organic operating profit growth ahead of sales growth. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 02:58 ET (07:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.